Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Background:
The drug Jardiance treats diabetes. It lowers blood sugar by increasing glucose the kidneys
excrete. This increases levels of ketones formed in the blood. The body makes ketones when it
does not have enough glucose for fuel. The brains of many people with age-related diseases
like Alzheimer s do not use glucose well. Brain use of ketones might improve mental ability.
Researchers want to see how Jardiance affects ketone levels, which could lead to ways to
improve brain health as people age.
Objectives:
To study how taking Jardiance affects ketone levels in people without diabetes.
Eligibility:
Adults at least 55 years old without diabetes
Design:
Participants will fast before all visits and sometimes during visits. Snacks or meals will be
provided.
Participants will be screened with medical history, physical exam, and blood tests.
At 3 study visits over about 4 weeks, participants will:
Have a thin plastic tube inserted in an arm vein for frequent blood samples
Have their urine collected throughout the visit
Write what they eat and when in a diary
Answer questions about symptoms
Have an MRI/MRS scan. A strong magnetic field and radio waves will take pictures of the brain
and measure its blood flow and function. Participants will lie on a table that slides into
the scanner. They will wear a plastic device on their head and earplugs.
Participants will take the study drug once a day for 2 weeks.
Participants will get an activity monitor and walk about 2,000 steps most evenings.
A small sensor will be inserted in participants upper arm for 4 weeks to measure blood
glucose.
Participants will have a follow-up phone call.